Merck clears PFS endpoint in confirmatory trial for Keytruda in classical Hodgkin lymphoma
Classical Hodgkin lymphoma was the first blood cancer that Merck’s Keytruda was approved to treat. Three years after that OK arrived — kicking off a spate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
